Biggest EPS beats and misses, ranked by post-earnings price reaction. Free data, no paywall.
Beats and misses reported Oct 1 – Nov 18, 2026
Ranked by EPS surprise % (highest first). Price reaction = day after report.
| # | Symbol | Company | Sector | Date | EPS Actual | EPS Est. | Surprise | Price Reaction |
|---|---|---|---|---|---|---|---|---|
| 1 | iRhythm Technologies, Inc. | Healthcare | Nov 5, 2026 | $0.82↑ Raised | $0.02 | +5190% | -32.7% | |
Quentin Blackford, President and Chief Executive Officer Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels. | ||||||||
| 2 | Legend Biotech Corporation | Healthcare | Nov 10, 2026 | $0.14 | $0.01 | +1300% | -16.0% | |
| 3 | Alnylam Pharmaceuticals, Inc. | Healthcare | Oct 29, 2026 | $16.26 | $1.66 | +880% | -25.1% | |
| 4 | Centene Corp. | Healthcare | Oct 27, 2026 | $0.58↑ Raised | $0.10 | +506% | +1.0% | |
Sarah M. London, Chief Executive Officer Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated, | ||||||||
| 5 | AMN Healthcare Services, Inc. | Healthcare | Nov 5, 2026 | $1.16↓ Lowered | $0.23 | +406% | -24.2% | |
Cary Grace, President and Chief Executive Officer We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation, | ||||||||
| 6 | Vericel Corporation | Healthcare | Nov 5, 2026 | $0.27↑ Raised | $0.06 | +371% | +20.1% | |
Nick Colangelo, President and CEO The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders. | ||||||||
| 7 | GeneDx Holdings Corp. | Healthcare | Nov 9, 2026 | $0.28— Maintained | $0.07 | +284% | -16.6% | |
Katherine Stueland, CEO Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth. | ||||||||
| 8 | Omeros Corporation | Healthcare | Nov 16, 2026 | $0.06 | $0.02 | +200% | -16.6% | |
| 9 | CareDx, Inc | Healthcare | Oct 29, 2026 | $0.70↑ Raised | $0.25 | +175% | +22.2% | |
John Hanna, President and Chief Executive Officer We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy. | ||||||||
| 10 | Azenta, Inc. | Healthcare | Nov 10, 2026 | $0.28~ Mixed | $0.11 | +152% | +20.8% | |
Dr. Martin Madaus, Interim President and Chief Executive Officer We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency, | ||||||||
| 11 | Privia Health Group, Inc. | Healthcare | Nov 5, 2026 | $0.21↑ Raised | $0.09 | +132% | +9.0% | |
| 12 | BillionToOne, Inc. | Healthcare | Nov 4, 2026 | $0.32↑ Raised | $0.15 | +119% | +1.8% | |
Dr. Oguzhan Atay, Co-Founder and CEO Our third quarter was another period of strong execution, said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne. We delivered rapid growth with continued GAAP profitability, and more clinicians are choosing our tests in both prenatal and oncology. | ||||||||
| 13 | STAAR Surgical Company | Healthcare | Nov 4, 2026 | $0.11 | $0.05 | +117% | +6.2% | |
As we look ahead, our results give us the confidence to raise our ambitions. EVO ICL redefined the refractive landscape and is leading a market shift from laser to lens. | ||||||||
| 14 | BeOne Medicines AG | Healthcare | Nov 5, 2026 | $4.59↑ Raised | $2.34 | +96.2% | +7.7% | |
John V. Oyler, Co-Founder, Chairman, and CEO Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA. | ||||||||
| 15 | Xeris Biopharma Holdings, Inc. | Healthcare | Nov 5, 2026 | $0.06↑ Raised | $0.03 | +89.3% | +45.3% | |
John Shannon, Chairman and Chief Executive Officer As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company's near-term outlook | ||||||||
| 16 | Caris Life Sciences, Inc. | Healthcare | Nov 4, 2026 | $0.05↑ Raised | $0.03 | +77.9% | -21.6% | |
David Dean Halbert, Founder, Chairman and CEO This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year, said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences. | ||||||||
| 17 | Neurocrine Biosciences, Inc. | Healthcare | Nov 2, 2026 | $3.29↑ Raised | $1.91 | +72.3% | +13.4% | |
Kyle W. Gano, Ph.D., Chief Executive Officer Our third quarter performance marks another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines. | ||||||||
| 18 | TransMedics Group, Inc. | Healthcare | Nov 5, 2026 | $0.51↑ Raised | $0.30 | +71.4% | +21.3% | |
Waleed Hassanein, MD, President and Chief Executive Officer The third quarter of 2026 was the strongest in TransMedics' history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO. | ||||||||
| 19 | Progyny, Inc. | Healthcare | Nov 4, 2026 | $0.52↑ Raised | $0.31 | +66.1% | +18.3% | |
Pete Anevski, Chief Executive Officer We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season | ||||||||
| 20 | Sarepta Therapeutics, Inc. | Healthcare | Nov 5, 2026 | $0.13↑ Raised | $0.08 | +64.6% | -6.2% | |
Michael Severino, M.D., chief executive officer After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities. | ||||||||
| 21 | InnovAge Holding Corp. | Healthcare | Nov 3, 2026 | $0.14— Maintained | $0.09 | +63.0% | +9.8% | |
Patrick Blair, Chief Executive Officer We are pleased with our strong start to fiscal 2027, as continued census growth along with disciplined clinical and operational execution drove strong financial performance. | ||||||||
| 22 | LifeStance Health Group, Inc. | Healthcare | Nov 5, 2026 | $0.06↑ Raised | $0.04 | +62.6% | -3.1% | |
Dave Bourdon, CEO The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations," said Dave Bourdon, CEO of LifeStance. | ||||||||
| 23 | Inspire Medical Systems, Inc. | Healthcare | Nov 2, 2026 | $0.14↓ Lowered | $0.09 | +60.9% | -7.9% | |
Tim Herbert, Chairman and CEO Looking further ahead, we were also pleased with the AMA Editorial Panel's September approval of a new CPT code for single lead HGNS devices, including the Inspire V system. | ||||||||
| 24 | Eton Pharmaceuticals, Inc. | Healthcare | Nov 5, 2026 | $0.50↑ Raised | $0.31 | +60.0% | +11.3% | |
Sean Brynjelsen, CEO Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule. | ||||||||
| 25 | AxoGen, Inc. | Healthcare | Oct 28, 2026 | $0.21↑ Raised | $0.13 | +59.9% | +31.5% | |
Michael Dale, President and CEO We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen's strategic plan priorities, | ||||||||
Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels.
Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated,
We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation,
The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders.
Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth.
We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances across our pipeline and clinical evidence, including in Cell Therapy.
We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency,
Our third quarter was another period of strong execution, said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne. We delivered rapid growth with continued GAAP profitability, and more clinicians are choosing our tests in both prenatal and oncology.
As we look ahead, our results give us the confidence to raise our ambitions. EVO ICL redefined the refractive landscape and is leading a market shift from laser to lens.
Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA.
As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company's near-term outlook
This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year, said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences.
Our third quarter performance marks another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines.
The third quarter of 2026 was the strongest in TransMedics' history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.
We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season
After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.
We are pleased with our strong start to fiscal 2027, as continued census growth along with disciplined clinical and operational execution drove strong financial performance.
The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations," said Dave Bourdon, CEO of LifeStance.
Looking further ahead, we were also pleased with the AMA Editorial Panel's September approval of a new CPT code for single lead HGNS devices, including the Inspire V system.
Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule.
We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen's strategic plan priorities,
Ranked by EPS miss % (worst first). Price reaction = day after report.
| # | Symbol | Company | Sector | Date | EPS Actual | EPS Est. | Surprise | Price Reaction |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics, Inc. | Healthcare | Oct 29, 2026 | -$0.62↑ Raised | $0.14 | -532% | -7.0% | |
Matthew B. Klein, M.D., Chief Executive Officer We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year. | ||||||||
| 2 | Liquidia Corporation | Healthcare | Nov 10, 2026 | -$2.64 | $0.96 | -375% | +7.4% | |
Dr. Roger Jeffs, Chief Executive Officer Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient's therapy. | ||||||||
| 3 | Hims & Hers Health, Inc. | Healthcare | Nov 9, 2026 | -$0.14~ Mixed | $0.06 | -349% | -16.6% | |
Andrew Dudum, co-founder and CEO In healthcare, whoever owns the customer relationship wins, and that's exactly what we're building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them. | ||||||||
| 4 | Innoviva, Inc. | Healthcare | Nov 4, 2026 | -$1.03— Maintained | $0.52 | -300% | -8.1% | |
Pavel Raifeld, Chief Executive Officer IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales. | ||||||||
| 5 | UroGen Pharma Ltd. | Healthcare | Nov 4, 2026 | -$0.03↓ Lowered | $0.11 | -128% | -25.2% | |
Liz Barrett, President and Chief Executive Officer We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity. | ||||||||
| 6 | Arcutis Biotherapeutics, Inc. | Healthcare | Nov 4, 2026 | $0.06↑ Raised | $0.18 | -66.7% | -15.6% | |
Frank Watanabe, president and chief executive officer Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. | ||||||||
| 7 | Harmony Biosciences Holdings, Inc. | Healthcare | Nov 4, 2026 | $0.81— Maintained | $1.09 | -25.7% | -12.3% | |
Jeffrey Dayno, MD, President and CEO As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation | ||||||||
| 8 | Integer Holdings Corporation | Healthcare | Oct 29, 2026 | $1.34 | $1.68 | -20.2% | -0.0% | |
| 9 | Penumbra, Inc. | Healthcare | Oct 29, 2026 | $1.07 | $1.20 | -10.8% | +0.2% | |
| 10 | DENTSPLY SIRONA Inc. | Healthcare | Nov 5, 2026 | $0.29~ Mixed | $0.31 | -6.1% | -11.2% | |
Dan Scavilla, President and Chief Executive Officer We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions | ||||||||
| 11 | Alphatec Holdings, Inc. | Healthcare | Oct 29, 2026 | $0.09~ Mixed | $0.10 | -5.4% | -38.1% | |
Pat Miles, Chairman and Chief Executive Officer Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment, said Pat Miles, Chairman and Chief Executive Officer. | ||||||||
| 12 | LeMaitre Vascular, Inc. | Healthcare | Nov 4, 2026 | $0.65— Maintained | $0.69 | -5.3% | +3.6% | |
George LeMaitre, Chairman/CEO We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft's international launch and the continued growth of RestoreFlow Allografts. | ||||||||
| 13 | United Therapeutics Corporation | Healthcare | Nov 4, 2026 | $5.71 | $6.01 | -5.0% | +1.2% | |
Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve, | ||||||||
| 14 | Bio-Techne Corporation | Healthcare | Nov 4, 2026 | $0.42 | $0.44 | -4.5% | 0.0% | |
| 15 | Pacira BioSciences, Inc. | Healthcare | Nov 5, 2026 | $0.72 | $0.75 | -4.3% | +0.1% | |
| 16 | TG Therapeutics, Inc. | Healthcare | Nov 9, 2026 | $0.35 | $0.36 | -2.6% | +5.9% | |
| 17 | The Pennant Group, Inc. | Healthcare | Nov 4, 2026 | $0.35— Maintained | $0.36 | -2.1% | -2.9% | |
Brent Guerisoli, CEO Pennant delivered a solid quarter and strong year-over-year improvement across the organization, said Brent Guerisoli, the Company's Chief Executive Officer. | ||||||||
We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year.
Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient's therapy.
In healthcare, whoever owns the customer relationship wins, and that's exactly what we're building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.
IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales.
We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity.
Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position.
As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation
We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions
Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment, said Pat Miles, Chairman and Chief Executive Officer.
We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft's international launch and the continued growth of RestoreFlow Allografts.
United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve,
Pennant delivered a solid quarter and strong year-over-year improvement across the organization, said Brent Guerisoli, the Company's Chief Executive Officer.